sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global 3D printed drugs Market Size Study, By Drug (Spritam and Others) and Regional (US and Rest of the World) Forecasts, 2017-2025

Global 3D printed drugs Market Size Study, By Drug (Spritam...

Home / Categories / Healthcare
Global 3D printed drugs Market Size Study, By Drug (Spritam and Others) and Regional (US and Rest of the World) Forecasts, 2017-2025
Global 3D printed drugs Market...
Report Code
RO1/103/1040

Publish Date
20/Mar/2018

Pages
180-200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..

Global 3D printed drugs industry valued approximately USD XX Million in 2016 is anticipated to grow with a healthy growth rate of XX% over the forecast period 2017-2025. 3D printed drugs are created by 3D printing technology which are used to treat patients who suffering from dysphagia. This medicine is easy to swallow and helpful for patients suffering from dysphagia. Increase in demand for fast soluble drugs which can disperse easily in the mouth is the key factor that gives growth to the global 3D printed drugs market. Furthermore, rising incidence of epilepsy cases, continues technological developments in 3D printing technique, and growing awareness for 3D printing technology in the developing countries are the major drivers of the market. However, concerns such as blueprint hacking and mislabeling of blueprint are going to hamper the market growth. Moreover, dicey regulatory scenario is another major restraint.


In 2016, Spritam is first 3D printed drug receive approval from the FDA. It is launched by Aprecia Pharmaceuticals. This medicine is currently active only in the U.S. region.


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

Drug:
§ Spritam
§ Others
Regions:
§ North America
o U.S.
§ Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2015
Base year – 2016
Forecast period – 2017 to 2025
Some of the key manufacturers involved in the market Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, 3D Printer Drug Machine, and FabRx Ltd. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Target Audience of the 3D printed drugs Market Study:

§ Key Consulting Companies & Advisors
§ Large, medium-sized, and small enterprises
§ Venture capitalists
§ Value-Added Resellers (VARs)
§ Third-party knowledge providers
§ Investment bankers
§ Investors

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com